BCM
ACTU

Bridgeway Capital Management’s Actuate Therapeutics ACTU Stock Holding History

Bridgeway Capital Management’s Portfolio ACTU Stock Details ACTU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$84.9K Hold
30,982
– – ﹤0.01% 1139
2025
Q4 		$190K Buy
+30,982
New +$213K ﹤0.01% 1030

Other funds holding ACTU

BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CCM
Connective Capital Management Palo Alto, California $121M AUM 39.82% 1-Year Est. Return
PVM
Palogic Value Management Dallas, Texas $237M AUM 5.37% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bridgeway Capital Management's ACTU Position: Q1 2026 in Review

Bridgeway Capital Management held its Actuate Therapeutics (ACTU) position steady in Q1 2026 at 30,982 shares worth $84.9K. The position accounts for ﹤0.01% of the portfolio, ranked #1139.

Bridgeway Capital Management first reported a position in ACTU in Q4 2025 and has held it in 2 quarters since. The position peaked at $190K in Q4 2025. 61 funds tracked by Wall St. Rank hold ACTU as of Q1 2026.

  • Bridgeway Capital Management held 30,982 shares of Actuate Therapeutics worth $84.9K as of Q1 2026.
  • Bridgeway Capital Management left its Actuate Therapeutics share count unchanged in Q1 2026.
  • Actuate Therapeutics made up ﹤0.01% of Bridgeway Capital Management's portfolio in Q1 2026, its #1139 holding.
  • Bridgeway Capital Management first reported a position in Actuate Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Bridgeway Capital Management's Actuate Therapeutics position peaked at $190K in Q4 2025.
  • 61 funds tracked by Wall St. Rank held Actuate Therapeutics as of Q1 2026.

Based on Bridgeway Capital Management's 13F filing for Q1 2026, filed 15 May 2026.